India TV13d
US FDA approves Novo Nordisk's Ozempic to reduce risk of kidney diseases in diabetic patients
The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...
Hosted on MSN14d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...
Yahoo News Canada14d
US FDA approves Novo Nordisk's diabetes drug to reduce risk of worsening kidney disease
(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type ...
NBC Washington15d
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...
Investing15d
Novo Nordisk's SWOT analysis: obesity drug leader faces supply hurdles
Novo Nordisk (NYSE:NVO) A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE ...
Reuters15d
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
Jan 28 (Reuters) - The U.S. FDA has approved Novo Nordisk's (NOVOb.CO), opens new ... Novo's blockbuster diabetes drug Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and ...